Blood protein panel may help forecast ALS symptom onset in gene carriers

For people serving in the U.S. armed forces, the risk of developing amyotrophic lateral sclerosis (ALS) varies by military branch and rank, a study suggested. The study found the risk of ALS is lower among people in the Marines or Army than among those who served in the Coast…

Mutations in the NEK1 gene — a major genetic cause of amyotrophic lateral sclerosis (ALS) — can disrupt the molecular machinery that cells normally rely on to make new proteins, according to a new study. The results shed new light on the molecular mechanisms by which certain mutations can contribute…

Abnormal levels of certain fatty molecules in the body — which are broken down by metabolism to support daily functions —may increase the risk of amyotrophic lateral sclerosis (ALS), according to a new study. The research, which was based on genetic data to reduce the influence of external factors,…

My brother and his family visited from out of town for a few days, so I planned a couple activities away from home and hired a caregiver for my husband, Todd, who has ALS and is paralyzed. Now that his neck is very weak and he needs noninvasive…

Even though I know my brain is in charge, there are days when my body seems to have a mind of its own. When that happens, I remind myself that my body is not the enemy. In fact, there is no enemy at all — just me, misunderstanding my…

People whose amyotrophic lateral sclerosis (ALS) begins with speech and swallowing problems, known as bulbar onset, are typically diagnosed about four months sooner than those whose disease begins with arm or leg weakness, known as limb onset. That’s according to a pooled analysis of data from 13 studies across…

Before my daughter, Marissa, was diagnosed with ALS in September 2022 at age 30, I was convinced that her symptoms could be attributed to anything except ALS. Denial made it hard to accept reality. Since then, my world has been turned upside down. Early in 2022, Marissa began experiencing…

Neurosense Therapeutics announced that it’s preparing a new drug submission to Health Canada — following a meeting with the regulatory agency — to seek approval of PrimeC, its combination therapy for amyotrophic lateral sclerosis (ALS), in the North American nation. During that meeting, the U.S. biotech company presented…

The U.S. House of Representatives has passed legislation that would renew the ACT for ALS, a landmark federal law that supports amyotrophic lateral sclerosis (ALS) research and helps people with the disease access promising experimental therapies. The ACT for ALS Reauthorization Act (H.R. 8205) will now move to…